Skip to main content

Advertisement

SpringerLink
Log in

Non-insulin therapies for type 2 diabetes

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: US non-insulin antidiabetes sales and prescriptions, 2006.

References

  1. Wild, S., Roglic, G., Green, A., Sicree, R. & King, H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047–1053 (2004).

    Article  Google Scholar 

  2. American Diabetes Association (ADA). National Diabetes Fact Sheet United States, 2005. ADA web site [online], (2005).

  3. Pharmaprojects. Therapy Analysis — R&D Annual Review: Therapeutic areas — diabetes pipeline still fattening. Pharmaprojects web site [online], (2007).

  4. Koro, C. E., Bowlin, S. J., Bourgeois, N. & Fedder, D. O. Glycemic control from 1988 to 2000 among U. S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 27, 17–20 (2004).

    Article  Google Scholar 

Download references

Acknowledgements

The authors thank Joseph Avruch for his comments.

Author information

Authors and Affiliations

  1. Mona Ashiya, Ph.D. and Richard E.T. Smith, Ph.D. are biotech analysts at JPMorgan Securities, 277 Park Avenue, New York 10172 USA.,

    Mona Ashiya & Richard E. T. Smith

Authors
  1. Mona Ashiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard E. T. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mona Ashiya.

Ethics declarations

Competing interests

JPMorgan has an investment banking relationship with GlaxoSmithKline, Eli Lilly, Takeda Pharmaceuticals, Novo Nordisk, Merck, Novartis, AstraZeneca, Bristol–Myers Squibb, Sanofi–Aventis, Roche, OSI Pharmaceuticals, Wyeth and Incyte.

Related links

Related links

FURTHER INFORMATION

OMIM

Type 2 diabetes

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ashiya, M., Smith, R. Non-insulin therapies for type 2 diabetes. Nat Rev Drug Discov 6, 777–778 (2007). https://doi.org/10.1038/nrd2420

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2420

  • Springer Nature Limited

This article is cited by

Search

Navigation